Kixta 100mg Capsule contains Palbociclib, a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used primarily in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Palbociclib works by inhibiting CDK4 and CDK6 enzymes, which play a crucial role in cell cycle progression from the G1 phase to the S phase, thereby preventing cancer cell proliferation. Kixta is indicated for use in combination with endocrine therapies such as letrozole or fulvestrant to improve progression-free survival in postmenopausal women and men with HR+/HER2- advanced breast cancer. The recommended dosage is 125 mg orally once daily for 21 consecutive days followed by 7 days off treatment, constituting a 28-day cycle, with dose adjustments based on tolerability and hematologic parameters. Common adverse effects include neutropenia, leukopenia, fatigue, nausea, and infections, necessitating regular blood count monitoring during therapy. Kixta should be used under strict medical supervision, with caution in patients with hepatic or renal impairment. It is contraindicated in patients with hypersensitivity to Palbociclib or any excipients. This medication is part of a targeted therapy approach aimed at improving clinical outcomes in breast cancer management.